While a drastic jump in Orexigen Therapeutics' stock (OREX) was not seen (due to many factors) after OREX's close competitor, Arena Pharmaceuticals (ARNA), received a negative review by FDA's advisory panel of the company's obesity drug candidate, a 'modest' gain of > 7% was sufficient to support the idea that investors have not completely given up on the company. What's more interesting is the light trading volume behind the climbing share price, signifying a strong interest in the stock and a potential run in the near term. Could encouraging 'insider information' have leaked to a small group of people to prompt the buying momentum?!?! Perhaps. Investors should be cautious, however, about hanging on to the stock too long as ARNA and VVUS' PDUFA dates quickly approach (rejections may cause OREX to swing dramatically in either direction. *OREX was recommended post ARNA's 70% tumble after hours on Sept. 17, 2010*
No comments:
Post a Comment